Robert Tansley
Board Director
Robert is a Partner at Cambridge Innovation Capital focusing on Life Sciences. After seven years working in hospital medicine, Robert worked in development and regulatory roles at Sanofi, the MHRA and Roche.
Robert then spent a decade at early stage biotech companies including Arakis (sold to Sosei Inc), founder and CEO at Treague, founding CEO of the University of Copenhagen spin -out Avilex Pharma and part of the founding management team of KalVista (Nasdaq: KALV).
Robert qualified in medicine from UCL. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge.
Robert manages CIC’s investments in Carrick Therapeutics, CMR Surgical, Exvastat, Gyroscope, Inivata, Microbiotica, PetMedix, Pretzel Therapeutics.
